RU98118578A - Способ профилактики отсроченной рвоты - Google Patents
Способ профилактики отсроченной рвотыInfo
- Publication number
- RU98118578A RU98118578A RU98118578/14A RU98118578A RU98118578A RU 98118578 A RU98118578 A RU 98118578A RU 98118578/14 A RU98118578/14 A RU 98118578/14A RU 98118578 A RU98118578 A RU 98118578A RU 98118578 A RU98118578 A RU 98118578A
- Authority
- RU
- Russia
- Prior art keywords
- daily dose
- administered
- specified
- hours
- vomiting
- Prior art date
Links
- 206010047700 Vomiting Diseases 0.000 title claims 4
- 230000003111 delayed Effects 0.000 title claims 3
- 238000002512 chemotherapy Methods 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 229940009456 Adriamycin Drugs 0.000 claims 1
- 229960001561 Bleomycin Drugs 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- 229960004397 Cyclophosphamide Drugs 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims 1
- 229960003048 Vinblastine Drugs 0.000 claims 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 229960004528 Vincristine Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004503 metoclopramide Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylaxis Effects 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
Claims (9)
1. Способ профилактики отсроченной рвоты, включающий стадии: введения внутриносовым способом фармацевтически приемлемого назального аэрозольного препарата метоклопрамида для доставки терапевтически эффективной и медицински приемлемой суточной дозы для указанной профилактики.
2. Способ по п.1, отличающийся тем, что указанная суточная доза составляет примерно 40 - 120 мг/сутки.
3. Способ по п.1, отличающийся тем, что указанная суточная доза составляет 60 мг/сутки.
4. Способ по п.1, отличающийся тем, что указанную суточную дозу делят на 3 или 4 равные меньшие дозы и вводят с равными интервалами в течение 24 ч.
5. Способ по п.4, отличающийся тем, что указанные меньшие дозы составляют 20 мг и их вводят через каждые 8 ч.
6. Способ по п.1, отличающийся тем, что указанная суточная доза составляет 1,95 - 3,90 мг/кг.
7. Способ по п.1, отличающийся тем, что указанную дозу вводят для профилактики отсроченной рворы, вызванной химиотерапией.
8. Способ по п.7, отличающийся тем, что указанная рвота вызвана химиотерапевтическими агентами, выбранными из группы, состоящей из цисплатина, циклофосфамида, адриамицина, винбластина, метотрексата, этопозида, блеомицина, винкристина и их комбинаций.
9. Способ по п.7, отличающийся тем, что указанную суточную дозу вводят в течение 24 - 168 ч после завершения указанной химиотерапии.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/616,121 | 1996-03-14 | ||
| US08/616,121 US5760086A (en) | 1996-03-14 | 1996-03-14 | Nasal administration of agents for treatment of delayed onset emesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU98118578A true RU98118578A (ru) | 2000-08-20 |
| RU2181588C2 RU2181588C2 (ru) | 2002-04-27 |
Family
ID=24468120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU98118578/14A RU2181588C2 (ru) | 1996-03-14 | 1997-03-13 | Способ профилактики отсроченной рвоты |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5760086A (ru) |
| EP (1) | EP0891186B1 (ru) |
| JP (1) | JP2000507234A (ru) |
| KR (1) | KR100420673B1 (ru) |
| CN (1) | CN1217657A (ru) |
| AT (1) | ATE489137T1 (ru) |
| AU (1) | AU707467B2 (ru) |
| BG (1) | BG102780A (ru) |
| CA (1) | CA2248968C (ru) |
| CZ (1) | CZ289797B6 (ru) |
| DE (1) | DE69740060D1 (ru) |
| DK (1) | DK0891186T3 (ru) |
| EE (1) | EE03665B1 (ru) |
| ES (1) | ES2357520T3 (ru) |
| IL (1) | IL126199A (ru) |
| NO (1) | NO984245L (ru) |
| NZ (1) | NZ331991A (ru) |
| PL (1) | PL328940A1 (ru) |
| PT (1) | PT891186E (ru) |
| RU (1) | RU2181588C2 (ru) |
| SK (1) | SK282695B6 (ru) |
| UA (1) | UA57733C2 (ru) |
| WO (1) | WO1997033573A1 (ru) |
| YU (1) | YU40398A (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770262B2 (en) * | 2000-03-30 | 2004-08-03 | Questcor Pharmaceuticals, Inc. | Nasal administration of agents for the treatment of gastroparesis |
| PL2343987T3 (pl) * | 2008-11-11 | 2013-05-31 | Unilever Nv | Herbaciana kompozycja |
| PL2376075T3 (pl) * | 2008-12-22 | 2015-08-31 | Evoke Pharma Inc | Donosowe preparaty z metoklopramidu |
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| US20110165143A1 (en) * | 2010-01-06 | 2011-07-07 | The Regents Of The University Of Colorado, A Body Corporate | Modulation of caspases and therapeutical applications |
| CN103957707A (zh) | 2011-08-25 | 2014-07-30 | 伊沃克制药公司 | 与女性胃轻瘫有关的症状的治疗 |
| FR2980976B1 (fr) * | 2011-10-10 | 2015-10-16 | Mohamed Skiba | Composition pharmaceutique pour l'administration par voie nasale de la metopimazine |
| CN104606136A (zh) * | 2015-01-06 | 2015-05-13 | 中国人民解放军军事医学科学院毒物药物研究所 | 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途 |
| US11517545B2 (en) | 2016-12-15 | 2022-12-06 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4624965A (en) * | 1984-11-15 | 1986-11-25 | Nastech Pharmaceutical Co., Inc. | Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same |
-
1996
- 1996-03-14 US US08/616,121 patent/US5760086A/en not_active Expired - Lifetime
-
1997
- 1997-03-13 EE EE9800295A patent/EE03665B1/xx not_active IP Right Cessation
- 1997-03-13 PL PL97328940A patent/PL328940A1/xx unknown
- 1997-03-13 CZ CZ19982922A patent/CZ289797B6/cs not_active IP Right Cessation
- 1997-03-13 EP EP97915060A patent/EP0891186B1/en not_active Expired - Lifetime
- 1997-03-13 DK DK97915060.4T patent/DK0891186T3/da active
- 1997-03-13 ES ES97915060T patent/ES2357520T3/es not_active Expired - Lifetime
- 1997-03-13 JP JP9532838A patent/JP2000507234A/ja not_active Ceased
- 1997-03-13 PT PT97915060T patent/PT891186E/pt unknown
- 1997-03-13 YU YU40398A patent/YU40398A/sh unknown
- 1997-03-13 KR KR10-1998-0707237A patent/KR100420673B1/ko not_active IP Right Cessation
- 1997-03-13 UA UA98105338A patent/UA57733C2/ru unknown
- 1997-03-13 DE DE69740060T patent/DE69740060D1/de not_active Expired - Lifetime
- 1997-03-13 NZ NZ331991A patent/NZ331991A/xx not_active IP Right Cessation
- 1997-03-13 WO PCT/US1997/003974 patent/WO1997033573A1/en active IP Right Grant
- 1997-03-13 RU RU98118578/14A patent/RU2181588C2/ru active IP Right Revival
- 1997-03-13 AT AT97915060T patent/ATE489137T1/de active
- 1997-03-13 SK SK1259-98A patent/SK282695B6/sk unknown
- 1997-03-13 CN CN97194427A patent/CN1217657A/zh active Pending
- 1997-03-13 IL IL12619997A patent/IL126199A/en not_active IP Right Cessation
- 1997-03-13 AU AU22102/97A patent/AU707467B2/en not_active Ceased
- 1997-03-13 CA CA002248968A patent/CA2248968C/en not_active Expired - Lifetime
-
1998
- 1998-09-14 NO NO984245A patent/NO984245L/no not_active Application Discontinuation
- 1998-09-18 BG BG102780A patent/BG102780A/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL109496A0 (en) | Substituted pyrrolidin-3-yl-alkyl-piperidines and pharmaceutical compositions containing them | |
| CZ187097A3 (cs) | Farmaceutický prostředek | |
| EP0457195A3 (en) | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | |
| CA2081604A1 (en) | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | |
| IL212075A0 (en) | Pharmaceutical compositions comprising a combination of a renin inhibitor and at least one therapeutic agent and uses thereof for the manufacture of medicaments for the prevention of, delay of progression of, or treatment of a disease | |
| CA2427815A1 (en) | Controlled release hydrocodone formulations | |
| CA2159580A1 (en) | Pharmaceutical Compositions Containing Polyvinylpyrrolidone and a Tri-Ester and Process of Manufacture Thereof | |
| CA2118812A1 (en) | 5-ht4 receptor antagonists | |
| GB9914486D0 (en) | Medicaments | |
| RU98118578A (ru) | Способ профилактики отсроченной рвоты | |
| CA2382919A1 (en) | Bicyclic imidazo-3-yl-amine derivatives | |
| CA2065285A1 (en) | Antimalarial compositions | |
| EP0664128A4 (en) | PHARMACEUTICAL AGENT FOR INHIBITING TUMORNESCROSE FACTOR PRODUCTION. | |
| CA2445519A1 (en) | Method for manufacturing a low dose pharmaceutical composition | |
| EP2072049A3 (en) | Solid valsartan pharmaceutical compositions | |
| CA2176298A1 (en) | A single high dose fluoroquinolone treatment | |
| PL348419A1 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
| CA2140927A1 (en) | Platelet aggregation inhibitors | |
| CA2179733A1 (en) | Anticonvulsant pseudofructopyranose sulfamates | |
| CA2347750A1 (en) | Pharmaceutical composition containing decursin | |
| EP0647632A4 (ru) | ||
| CA2220019A1 (en) | Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation | |
| HUT59316A (en) | Process for producing solid, orally administrable dosage forms comprising iphosphamide as active ingredient | |
| HK1041000B (zh) | 新型嘧啶衍生物及其製備方法 | |
| CA2340427A1 (en) | Non-sedating diphenhydramine metabolites |